Documents

Use of a new plant extract-based product in inflammatory diseases of the paranasal sinuses.
Results of its administration

KHECHINASHVILI S.
Academician, Doctor of Medicine,
State Academy of Medicine in Tbilisi,
Department of Otorhinolaryngology

KHOKHASHVILI P.
State Academy of Medicine in Tbilisi,
Department of Otorhinolaryngology

Therapeutics and Clinical Risk Management.
Special Issue in Spanish. Supplement I 2006.
Therapeutics and clinical risk management 2006 - PDF


ABSTRACT

The incidence of rhinosinusitis continues to increase year after year, in spite of the treatments currently available. Although antibiotics have been used extensively in their treatment, their insufficient efficacy has sometimes contributed to worsening the problem, as their indiscriminate use eliminates the very necessary saprophytic flora and generates strains that are resistant to the antibiotics. This has led several authors to reflect on the need for a more rational use of the medication that is currently being used in the treatment of rhinosinusitis.

In recent years, a product has been developed that when applied in the nasal cavity, acts by activating the physiological mechanisms by which the nasal mucosa is cleared, facilitating natural secretion and thereby clearing and draining the accumulated purulent matter. Radiographic assessments were performed, including computerised axial tomography, in 50 patients.

The results of our study show that the plant extracts effectively facilitate drainage of the secretions that accumulate in rhinosinusitis, favouring symptom relief for the patient.

Use of a new plant extract-based product in inflammatory diseases...- Full article

Therapeutics and clinical risk management 2006 - Index

Assessment of a new plant extract-based product in rhinosinusitis - Next abstract

Hartington Pharma owns Nasodren® for sinusitis treatment